FIELD: biochemistry.
SUBSTANCE: invention relates to an anti-CD19 antibody or antigen-binding fragment thereof, as well as to a conjugate, a chimeric antigen receptor and a pharmaceutical composition containing said antibody or fragment thereof. Also disclosed is a nucleic acid encoding said antibody, a nucleic acid encoding said chimeric antigen receptor, as well as a cell containing said nucleic acid. Invention also relates to a method of treating a disease or disorder in which CD19 is expressed.
EFFECT: invention enables effective treatment of a disease or disorder in which CD19 is expressed.
44 cl, 18 dwg, 9 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
ANTI-IDIOTYPIC ANTIBODIES AND METHODS RELATED TO THEM | 2017 |
|
RU2773355C2 |
ANTIBODIES TO CHIMERIC ANTIGEN RECEPTORS DERIVED FROM 4G7 | 2020 |
|
RU2826051C2 |
LABELED CHIMERIC EFFECTOR MOLECULES AND RECEPTORS THEREOF | 2014 |
|
RU2729463C2 |
CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
REAGENTS FOR REPRODUCTION OF CELLS EXPRESSING RECOMBINANT RECEPTORS | 2018 |
|
RU2783956C2 |
ANTIBODY AGENTS SPECIFIC TO HUMAN CD19, AND THEIR APPLICATIONS | 2016 |
|
RU2773317C2 |
CELL | 2015 |
|
RU2768019C2 |
METHOD AND COMPOSITIONS FOR CELL IMMUNOTHERAPY | 2013 |
|
RU2700765C2 |
HIV ANTIBODY COMPOSITIONS AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2757135C2 |
Authors
Dates
2021-01-22—Published
2015-08-28—Filed